Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Operating Expenses (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Other Operating Expenses for 16 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 28.15% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.9 million through Dec 2025, up 6.88% year-over-year, with the annual reading at $18.9 million for FY2025, 6.88% up from the prior year.
  • Other Operating Expenses hit $5.3 million in Q4 2025 for Vanda Pharmaceuticals, up from $4.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $6.8 million in Q3 2021 to a low of $3.2 million in Q3 2023.
  • Historically, Other Operating Expenses has averaged $5.2 million across 5 years, with a median of $5.1 million in 2024.
  • Biggest five-year swings in Other Operating Expenses: tumbled 70.04% in 2021 and later grew 28.15% in 2025.
  • Year by year, Other Operating Expenses stood at $6.3 million in 2021, then increased by 1.31% to $6.4 million in 2022, then plummeted by 33.42% to $4.2 million in 2023, then decreased by 2.53% to $4.1 million in 2024, then increased by 28.15% to $5.3 million in 2025.
  • Business Quant data shows Other Operating Expenses for VNDA at $5.3 million in Q4 2025, $4.4 million in Q3 2025, and $4.2 million in Q2 2025.